EUVIMEDEUVIMED entdecken
Crossref

Synthesis and preclinical evaluation of small molecule-based radiotracers for PET imaging of PD-L1 expression and dynamics

Gaochao Lv iD, Nan Zhang, Junyi Zhu, Xin Hu, Qianhui Wang, Bingqing Qiu, Qingzhu Liu, Ling Qiu, Jianguo Lin

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07290-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Gaochao Lv und 8 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, Ch…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Positron-Emission Tomography, Radiopharmaceuticals, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Project 333 of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Small molecule-based radiotracers offer several potential advantages in positron emission tomography (PET) imaging, and are therefore a promising approach for non-invasively and accurately monitoring of programmed death ligand 1 (PD-L1) expression in vivo. In this study, two small-molecule radiotracers were developed to assess PD-L1 expression and dynamics during treatments. METHODS: [18F]LG-2 and [18F]LG-3 were designed based on a phenoxymethyl-biphenyl scaffold with a tris-(hydroxymethyl)-aminomethane terminal group. The radiolabeling was achieved by a two-step method through the "click" chemistry. Cellular uptake assays in different tumor cells were performed to determine the specificity of the two tracers to PD-L1. The ability of [18F]LG-2 and [18F]LG-3 to detect PD-L1 expression in vivo as well as to monitor PD-L1 dynamics during chemotherapy and immunotherapy was investigated via PET imaging. RESULTS: The radiolabeling of [18F]LG-2 and [18F]LG-3 was achieved with overall radiochemical yield of 15 ± 3% for [18F]LG-2 and 18 ± 5% for [18F]LG-3. In vitro cell uptake studies in tumor cells with varying PD-L1 levels demonstrated the specific binding of these tracers to PD-L1. PET imaging in mice bearing B16-F10 tumors displayed comparable tumor uptake of 6.45 ± 0.38%ID/mL for [18F]LG-2 and 5.64 ± 0.02%ID/mL for [18F]LG-3, while [18F]LG-3 showed nearly a 50% reduction in uptake in the liver and intestines compared to [18F]LG-2. PET signals of [18F]LG-3 in A375-hPD-L1, A375-hPD-L1/A375 and A375 tumor-bearing mice demonstrated a strong and linear correlation with PD-L1 expression levels. The dynamic of PD-L1 status in tumors after cisplatin and PD-L1 inhibitor treatments were accurately evaluated with [18F]LG-3 PET imaging. CONCLUSION: The small-molecule radiotracer [18F]LG-3 is a promising candidate for evaluating PD-L1 expression and monitoring the dynamic of PD-L1 status during the treatment process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenPositron-Emission TomographyRadiopharmaceuticalsGene Expression Regulation, NeoplasticAnimalsMiceHumansCell Line, TumorChemistry Techniques, SyntheticRadioactive TracersFluorine RadioisotopesTissue Distribution

Stichwörter der Autor:innen

ImmunotherapyPD-L1PET imagingRadiopharmaceuticalSmall-molecule

Substanzen

B7-H1 AntigenRadiopharmaceuticalsRadioactive TracersFluorine RadioisotopesCD274 protein, human

Autor:innen und Institutionen

  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China. lvgaochao@jsinm.org.
  • Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China. lvgaochao@jsinm.org.
  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China.
  • Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China. linjianguo@jsinm.org.
  • Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China. linjianguo@jsinm.org.

ORCID-Profile: Gaochao Lv

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Project 333 of Jiangsu Province
  • Jiangsu Commission of Health
  • Jiangsu Province Capability Improvement Project through Science, Technology and Education

Zitieren

APA

Lv, G., Zhang, N., Zhu, J., Hu, X., Wang, Q., Qiu, B., Liu, Q., Qiu, L., & Lin, J. (2025). Synthesis and preclinical evaluation of small molecule-based radiotracers for PET imaging of PD-L1 expression and dynamics. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07290-3

Vancouver

Lv G, Zhang N, Zhu J, Hu X, Wang Q, Qiu B, et al. Synthesis and preclinical evaluation of small molecule-based radiotracers for PET imaging of PD-L1 expression and dynamics. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07290-3

BibTeX
@article{Lv2025,
  author = {Lv, Gaochao and Zhang, Nan and Zhu, Junyi and Hu, Xin and Wang, Qianhui and Qiu, Bingqing and Liu, Qingzhu and Qiu, Ling and Lin, Jianguo},
  title = {Synthesis and preclinical evaluation of small molecule-based radiotracers for PET imaging of PD-L1 expression and dynamics},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07290-3}
}
Kostenlos starten →